Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Emergent BioSolutions Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.58 |
Open* | 2.64 |
1-Year Change* | -70.14% |
Day's Range* | 2.45 - 2.64 |
52 wk Range | 1.81-16.66 |
Average Volume (10 days) | 1.35M |
Average Volume (3 months) | 28.43M |
Market Cap | 95.47M |
P/E Ratio | -100.00K |
Shares Outstanding | 51.88M |
Revenue | 1.10B |
EPS | -15.32 |
Dividend (Yield %) | N/A |
Beta | 1.00 |
Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 2.51 | -0.03 | -1.18% | 2.54 | 2.68 | 2.43 |
Mar 27, 2024 | 2.58 | 0.13 | 5.31% | 2.45 | 2.62 | 2.44 |
Mar 26, 2024 | 2.42 | -0.09 | -3.59% | 2.51 | 2.56 | 2.41 |
Mar 25, 2024 | 2.51 | 0.14 | 5.91% | 2.37 | 2.61 | 2.37 |
Mar 22, 2024 | 2.39 | -0.03 | -1.24% | 2.42 | 2.49 | 2.38 |
Mar 21, 2024 | 2.45 | -0.06 | -2.39% | 2.51 | 2.57 | 2.45 |
Mar 20, 2024 | 2.49 | 0.11 | 4.62% | 2.38 | 2.55 | 2.38 |
Mar 19, 2024 | 2.44 | 0.05 | 2.09% | 2.39 | 2.55 | 2.39 |
Mar 18, 2024 | 2.45 | 0.01 | 0.41% | 2.44 | 2.49 | 2.34 |
Mar 15, 2024 | 2.42 | 0.11 | 4.76% | 2.31 | 2.49 | 2.30 |
Mar 14, 2024 | 2.33 | 0.22 | 10.43% | 2.11 | 2.34 | 2.10 |
Mar 13, 2024 | 2.21 | -0.09 | -3.91% | 2.30 | 2.37 | 2.21 |
Mar 12, 2024 | 2.31 | -0.49 | -17.50% | 2.80 | 2.80 | 2.31 |
Mar 11, 2024 | 2.78 | 0.09 | 3.35% | 2.69 | 2.94 | 2.68 |
Mar 8, 2024 | 2.67 | -0.08 | -2.91% | 2.75 | 2.83 | 2.63 |
Mar 7, 2024 | 2.75 | 0.08 | 3.00% | 2.67 | 2.89 | 2.32 |
Mar 6, 2024 | 3.23 | -0.20 | -5.83% | 3.43 | 3.44 | 3.15 |
Mar 5, 2024 | 3.38 | 0.35 | 11.55% | 3.03 | 3.70 | 2.98 |
Mar 4, 2024 | 3.14 | -0.31 | -8.99% | 3.45 | 3.45 | 3.12 |
Mar 1, 2024 | 3.37 | 0.15 | 4.66% | 3.22 | 3.55 | 3.19 |
Emergent BioSolutions Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, May 24, 2024 | ||
Time (UTC) 13:00 | Country US
| Event Emergent BioSolutions Inc Annual Shareholders Meeting Emergent BioSolutions Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1120.9 | 1792.7 | 1555.4 | 1106 | 782.4 |
Revenue | 1120.9 | 1792.7 | 1555.4 | 1106 | 782.4 |
Cost of Revenue, Total | 693.7 | 716 | 506.7 | 433.5 | 322.3 |
Gross Profit | 427.2 | 1076.7 | 1048.7 | 672.5 | 460.1 |
Total Operating Expense | 1293.6 | 1440.1 | 1121.6 | 991.9 | 692.6 |
Selling/General/Admin. Expenses, Total | 340.3 | 348.4 | 303.3 | 273.5 | 202.5 |
Research & Development | 193 | 234 | 205.5 | 226.2 | 142.8 |
Operating Income | -172.7 | 352.6 | 433.8 | 114.1 | 89.8 |
Interest Income (Expense), Net Non-Operating | -37.3 | -34.5 | -31.3 | -38.4 | -9.9 |
Other, Net | -11.7 | -3.7 | 4.7 | 1.7 | 1.6 |
Net Income Before Taxes | -221.7 | 314.4 | 407.2 | 77.4 | 81.5 |
Net Income After Taxes | -223.8 | 230.9 | 305.1 | 54.5 | 58.4 |
Net Income Before Extra. Items | -223.8 | 230.9 | 305.1 | 54.5 | 58.4 |
Total Extraordinary Items | 0 | 4.3 | |||
Net Income | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 |
Income Available to Common Excl. Extra. Items | -223.8 | 230.9 | 305.1 | 54.5 | 58.4 |
Income Available to Common Incl. Extra. Items | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 |
Diluted Net Income | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 |
Diluted Weighted Average Shares | 50.1 | 54.1 | 53.8 | 52.4 | 51.4 |
Diluted EPS Excluding Extraordinary Items | -4.46707 | 4.26802 | 5.671 | 1.04008 | 1.13619 |
Diluted Normalized EPS | -4.38014 | 5.39747 | 6.31582 | 1.04008 | 1.13619 |
Depreciation / Amortization | 59.9 | 58.5 | 59.8 | 58.7 | 25 |
Unusual Expense (Income) | 6.7 | 83.2 | 46.3 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 337.9 | 165.1 | 330.7 | 240 | 242.7 |
Revenue | 337.9 | 165.1 | 330.7 | 240 | 242.7 |
Cost of Revenue, Total | 190.6 | 155.1 | 219.4 | 148.6 | 169.8 |
Gross Profit | 147.3 | 10 | 111.3 | 91.4 | 72.9 |
Total Operating Expense | 555.9 | 313.2 | 395.8 | 282 | 314.7 |
Selling/General/Admin. Expenses, Total | 91.4 | 100.5 | 94.2 | 80.2 | 81.1 |
Research & Development | 26 | 40.6 | 57.6 | 39.2 | 49.8 |
Depreciation / Amortization | 16.1 | 17 | 17.9 | 14 | 14 |
Operating Income | -218 | -148.1 | -65.1 | -42 | -72 |
Interest Income (Expense), Net Non-Operating | -28.6 | -17.9 | -12.8 | -8.5 | -7.8 |
Other, Net | -3.6 | 4.9 | 6.7 | -13.4 | -3 |
Net Income Before Taxes | -250.2 | -161.1 | -71.2 | -63.9 | -82.8 |
Net Income After Taxes | -261.3 | -183 | -88 | -75.7 | -56.4 |
Net Income Before Extra. Items | -261.3 | -183 | -88 | -75.7 | -56.4 |
Net Income | -261.3 | -183 | -88 | -75.7 | -56.4 |
Income Available to Common Excl. Extra. Items | -261.3 | -183 | -88 | -75.7 | -56.4 |
Income Available to Common Incl. Extra. Items | -261.3 | -183 | -88 | -75.7 | -56.4 |
Diluted Net Income | -261.3 | -183 | -88 | -75.7 | -56.4 |
Diluted Weighted Average Shares | 50.7 | 50.2 | 49.8 | 49.9 | 50 |
Diluted EPS Excluding Extraordinary Items | -5.15385 | -3.64542 | -1.76707 | -1.51703 | -1.128 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -2.18205 | -3.64542 | -1.67962 | -1.51703 | -1.128 |
Unusual Expense (Income) | 231.8 | 6.7 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1210.7 | 1272.1 | 1195.9 | 686.2 | 620.8 |
Cash and Short Term Investments | 642.6 | 576.1 | 621.3 | 167.8 | 112.2 |
Cash & Equivalents | 642.6 | 576.1 | 621.3 | 167.8 | 112.2 |
Total Receivables, Net | 158.4 | 274.7 | 272 | 275.3 | 271.1 |
Accounts Receivable - Trade, Net | 158.4 | 274.7 | 272 | 270.7 | 262.5 |
Total Inventory | 351.8 | 350.8 | 307 | 222.5 | 205.8 |
Prepaid Expenses | 57.9 | 70.3 | -4.6 | 20.4 | 31.5 |
Other Current Assets, Total | 0 | 0.2 | 0.2 | 0.2 | 0.2 |
Total Assets | 3166.6 | 2959 | 2883.2 | 2327.3 | 2229.4 |
Property/Plant/Equipment, Total - Net | 837 | 828.4 | 675.1 | 567 | 510.2 |
Property/Plant/Equipment, Total - Gross | 1220.8 | 1147.5 | 934.2 | 777.4 | 681.7 |
Accumulated Depreciation, Total | -383.8 | -319.1 | -259.1 | -210.4 | -171.5 |
Goodwill, Net | 218.2 | 224.9 | 266.7 | 266.6 | 259.7 |
Intangibles, Net | 728.8 | 604.6 | 663.1 | 741.9 | 811.6 |
Other Long Term Assets, Total | 171.9 | 29 | 82.4 | 65.6 | 27.1 |
Total Current Liabilities | 1229.9 | 373.8 | 384.5 | 216.3 | 200.4 |
Accounts Payable | 103.5 | 128.9 | 136.1 | 94.8 | 80.7 |
Accrued Expenses | 129 | 146.2 | 136.9 | 105.5 | 88.9 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 40.1 | 67.1 | 77.7 | 3.1 | 20.7 |
Total Liabilities | 1783.6 | 1340 | 1436.2 | 1238.8 | 1218.5 |
Total Long Term Debt | 448.5 | 809.4 | 841 | 798.4 | 784.5 |
Long Term Debt | 448.5 | 809.4 | 841 | 798.4 | 784.5 |
Other Liabilities, Total | 33.4 | 61.9 | 157.5 | 160.2 | 166.1 |
Total Equity | 1383 | 1619 | 1447 | 1088.5 | 1010.9 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 873.5 | 829.4 | 784.9 | 716.1 | 688.6 |
Retained Earnings (Accumulated Deficit) | 734 | 957.8 | 726.9 | 421.8 | 367.3 |
Treasury Stock - Common | -227.7 | -152.2 | -39.6 | -39.6 | -39.6 |
Other Equity, Total | 3.1 | -16.1 | -25.3 | -9.9 | -5.5 |
Total Liabilities & Shareholders’ Equity | 3166.6 | 2959 | 2883.2 | 2327.3 | 2229.4 |
Total Common Shares Outstanding | 50.1 | 51.3 | 53.1 | 51.7 | 51.2 |
Total Preferred Shares Outstanding | 0 | 0 | |||
Current Port. of LT Debt/Capital Leases | 957.3 | 31.6 | 33.8 | 12.9 | 10.1 |
Deferred Income Tax | 71.8 | 94.9 | 53.2 | 63.9 | 67.5 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total Current Assets | 777.7 | 1221.3 | 1210.7 | 1118.5 | 1084.2 |
Cash and Short Term Investments | 88.6 | 430.2 | 642.6 | 240.9 | 358.1 |
Cash & Equivalents | 88.6 | 430.2 | 642.6 | 240.9 | 358.1 |
Total Receivables, Net | 290.1 | 155.9 | 158.4 | 191.3 | 175 |
Accounts Receivable - Trade, Net | 290.1 | 155.9 | 158.4 | 191.3 | 175 |
Total Inventory | 354.3 | 367.9 | 351.8 | 546.3 | 425.5 |
Prepaid Expenses | 44.7 | 41.7 | 57.9 | 139.9 | 125.4 |
Other Current Assets, Total | 225.6 | 0 | 0.1 | 0.2 | |
Total Assets | 2178.8 | 2949.8 | 3166.6 | 2908.5 | 2735.4 |
Property/Plant/Equipment, Total - Net | 411.2 | 732.3 | 837 | 827.2 | 823.9 |
Property/Plant/Equipment, Total - Gross | 802.6 | 1107.5 | 1220.8 | 1193.4 | 1181.6 |
Accumulated Depreciation, Total | -391.4 | -375.2 | -383.8 | -366.2 | -357.7 |
Goodwill, Net | 218.2 | 218.2 | 218.2 | 224.9 | 224.9 |
Intangibles, Net | 592.8 | 608.9 | 728.8 | 722.7 | 576.6 |
Other Long Term Assets, Total | 178.9 | 169.1 | 171.9 | 15.2 | 25.8 |
Total Current Liabilities | 693.2 | 1215.7 | 1229.9 | 268.4 | 276.7 |
Accounts Payable | 108.3 | 124.2 | 103.5 | 103.8 | 106.2 |
Accrued Expenses | 104.4 | 81.5 | 129 | 124.1 | 120.6 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 455.2 | 950.7 | 957.3 | 21.2 | 31.6 |
Other Current Liabilities, Total | 25.3 | 59.3 | 40.1 | 19.3 | 18.3 |
Total Liabilities | 1222.5 | 1747.2 | 1783.6 | 1459.2 | 1222.2 |
Total Long Term Debt | 448 | 447.7 | 448.5 | 1032.1 | 793.6 |
Long Term Debt | 448 | 447.7 | 448.5 | 1032.1 | 793.6 |
Deferred Income Tax | 57.9 | 59.7 | 71.8 | 113.8 | 93.4 |
Other Liabilities, Total | 23.4 | 24.1 | 33.4 | 44.9 | 58.5 |
Total Equity | 956.3 | 1202.6 | 1383 | 1449.3 | 1513.2 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 895.8 | 878.2 | 873.5 | 860.1 | 849.2 |
Retained Earnings (Accumulated Deficit) | 289.7 | 551 | 734 | 822 | 897.7 |
Treasury Stock - Common | -227.7 | -227.7 | -227.7 | -227.7 | -227.7 |
Other Equity, Total | -1.6 | 1 | 3.1 | -5.2 | -6.1 |
Total Liabilities & Shareholders’ Equity | 2178.8 | 2949.8 | 3166.6 | 2908.5 | 2735.4 |
Total Common Shares Outstanding | 51.8 | 50.4 | 50.1 | 49.9 | 49.9 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -223.8 | 230.9 | 305.1 | 54.5 | 62.7 |
Cash From Operating Activities | -34.1 | 321.1 | 536 | 188 | 41.8 |
Cash From Operating Activities | 143.3 | 123.8 | 114.5 | 110.7 | 62.2 |
Deferred Taxes | -19 | 46.9 | -2.4 | -1.1 | 8.6 |
Non-Cash Items | 64.9 | 75.9 | 110 | 66.3 | 27.4 |
Cash Taxes Paid | 6.2 | 71.6 | 109.3 | 30.8 | 14 |
Cash Interest Paid | 33 | 30.4 | 21 | 34.5 | 10.2 |
Changes in Working Capital | 0.5 | -156.4 | 8.8 | -42.4 | -119.1 |
Cash From Investing Activities | -381.3 | -225 | -151 | -96.9 | -897.2 |
Capital Expenditures | -359.5 | -225 | -151 | -96.9 | -72.1 |
Other Investing Cash Flow Items, Total | -21.8 | 0 | -825.1 | ||
Cash From Financing Activities | 481.2 | -141 | 69.5 | -35.9 | 788.7 |
Financing Cash Flow Items | -0.9 | 0.9 | -25 | -57.8 | -22.3 |
Issuance (Retirement) of Stock, Net | -82.1 | -106 | 31.6 | 8.2 | 15.8 |
Issuance (Retirement) of Debt, Net | 564.2 | -35.9 | 62.9 | 13.7 | 795.2 |
Foreign Exchange Effects | 0.5 | -0.3 | -1 | 0.4 | -0.2 |
Net Change in Cash | 66.3 | -45.2 | 453.5 | 55.6 | -66.9 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -183 | -223.8 | -135.8 | -60.1 | -3.7 |
Cash From Operating Activities | -186.6 | -34.1 | -126.9 | -52.9 | -37.3 |
Cash From Operating Activities | 34.6 | 143.3 | 107.7 | 75.4 | 30.9 |
Deferred Taxes | -8.4 | -19 | 23 | 2.6 | 1.9 |
Non-Cash Items | 9.6 | 64.9 | 51.9 | 28.2 | 12 |
Cash Taxes Paid | 16.7 | 6.2 | 23.9 | 20 | 4.8 |
Cash Interest Paid | 21.6 | 33 | 26.7 | 14.8 | 11.7 |
Changes in Working Capital | -39.4 | 0.5 | -173.7 | -99 | -78.4 |
Cash From Investing Activities | -15.1 | -381.3 | -335.9 | -64.3 | -32.2 |
Capital Expenditures | -15.1 | -359.5 | -335.9 | -64.3 | -32.2 |
Cash From Financing Activities | -10.5 | 481.2 | 128.1 | -101.2 | -70.5 |
Financing Cash Flow Items | -2.1 | -0.9 | -2.7 | -2.4 | -4.5 |
Issuance (Retirement) of Debt, Net | -8.4 | 564.2 | 212.7 | -16.9 | -8.5 |
Foreign Exchange Effects | -0.2 | 0.5 | -0.6 | 0.4 | -0.3 |
Net Change in Cash | -212.4 | 66.3 | -335.3 | -218 | -140.3 |
Issuance (Retirement) of Stock, Net | 0 | -82.1 | -81.9 | -81.9 | -57.5 |
Other Investing Cash Flow Items, Total | -21.8 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com